- Home
- LENZ vs PRAA Comparison
LENZ vs PRAA Comparison
Compare LENZ & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- PRAA
- Stock Information
- Founded
- LENZ 2019
- PRAA 1996
- Country
- LENZ United States
- PRAA United States
- Employees
- LENZ N/A
- PRAA N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- PRAA Finance: Consumer Services
- Sector
- LENZ Health Care
- PRAA Finance
- Exchange
- LENZ Nasdaq
- PRAA Nasdaq
- Market Cap
- LENZ 819.1M
- PRAA 790.6M
- IPO Year
- LENZ 2021
- PRAA N/A
- Fundamental
- Price
- LENZ $29.94
- PRAA $14.68
- Analyst Decision
- LENZ Strong Buy
- PRAA Strong Buy
- Analyst Count
- LENZ 5
- PRAA 2
- Target Price
- LENZ $41.80
- PRAA $27.00
- AVG Volume (30 Days)
- LENZ 274.7K
- PRAA 511.5K
- Earning Date
- LENZ 05-07-2025
- PRAA 08-04-2025
- Dividend Yield
- LENZ N/A
- PRAA N/A
- EPS Growth
- LENZ N/A
- PRAA N/A
- EPS
- LENZ N/A
- PRAA 1.79
- Revenue
- LENZ N/A
- PRAA $1,128,557,000.00
- Revenue This Year
- LENZ N/A
- PRAA $2.73
- Revenue Next Year
- LENZ $544.79
- PRAA $7.34
- P/E Ratio
- LENZ N/A
- PRAA $8.21
- Revenue Growth
- LENZ N/A
- PRAA 25.02
- 52 Week Low
- LENZ $16.28
- PRAA $12.91
- 52 Week High
- LENZ $38.93
- PRAA $27.54
- Technical
- Relative Strength Index (RSI)
- LENZ 54.67
- PRAA 47.14
- Support Level
- LENZ $27.91
- PRAA $14.11
- Resistance Level
- LENZ $30.76
- PRAA $14.98
- Average True Range (ATR)
- LENZ 2.09
- PRAA 0.47
- MACD
- LENZ -0.14
- PRAA 0.13
- Stochastic Oscillator
- LENZ 38.41
- PRAA 53.29
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.